Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk.

Lesniak, Robert K; Nichols, R Jeremy; Montine, Thomas J

Lesniak, Robert K; Nichols, R Jeremy; Montine, Thomas J.

Afiliação

Lesniak RK; Medicinal Chemistry Knowledge Center, Sarafan Chemistry, Engineering and Medicine for Human Health, Stanford University, Stanford, CA, United States.
Nichols RJ; Department of Pathology, Stanford University, Stanford, CA, United States.
Montine TJ; Department of Pathology, Stanford University, Stanford, CA, United States.

Front Neurol ; 13: 1016040, 2022.

Article em En | MEDLINE | ID: mdl-36388213

Palavras-chave

LRRK2; Parkinson's disease; inhibitors; kinase; selectivity

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Revista: Front Neurol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google